Drug Report History

Return to report

Below you will find the report version history. When a report is updated, a new version of the report is created. The report history allows you to see the changes between versions. You can select two versions of the report to compare. The fields that were changed between versions will be highlighted in yellow.

The translation of reports creates two separate versions which is why some reports may not seem to have any differences. In this case, only the language field below will be highlighted in yellow.

Version v10-EN Version v2-FR
Language English French
Date Updated 2025-02-01 2024-11-14
Drug Identification Number 02531402 02531402
Brand name AURO-DAPAGLIFLOZIN AURO-DAPAGLIFLOZIN
Common or Proper name Auro-Dapagliflozin Auro-Dapagliflozin
Company Name AURO PHARMA INC AURO PHARMA INC
Ingredients DAPAGLIFLOZIN DAPAGLIFLOZIN
Strength(s) 5MG 5MG
Dosage form(s) TABLET TABLET
Route of administration ORAL ORAL
Packaging sizes (GTIN) (See additional packaging sizes) (See additional packaging sizes)
Additional packaging sizes 100 100
ATC code A10BK A10BK
ATC description BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS BLOOD GLUCOSE LOWERING DRUGS, EXCL. INSULINS
Reason for shortage Demand increase for the drug. Demand increase for the drug.
Anticipated start date
Actual start date 2024-11-14 2024-11-14
Estimated end date 2025-01-31 2025-01-31
Actual end date 2025-01-31
Shortage status Resolved Anticipated shortage
Tier 3 Status No No
Company comments Alternative Packs of 30's and 500's available.
Health Canada comments